I. Rubanovits

Correction to: How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

V. P. Misra, R. Jech, S. Ochudło, 2019, Journal of Neurology.

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

V. P. Misra, R. Jech, S. Ochudło, 2019, Journal of Neurology.

INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin

V. P. Misra, R. Jech, S. Ochudło, 2017, Journal of Neurology.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

D. Yarnitsky, M. Valis, H. Hartung, 2019, Journal of the peripheral nervous system : JPNS.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

G. L. Masson, D. Yarnitsky, S. Muley, 2018, The Lancet Neurology.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

G. L. Masson, D. Yarnitsky, M. Valis, 2019, Journal of the peripheral nervous system : JPNS.

Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson's disease and non-PD controls

D. Berg, T. Toomsoo, P. Taba, 2017, Psychiatry Research: Neuroimaging.

Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls.

Inga Liepelt-Scarfone, Daniela Berg, Toomas Toomsoo, 2019, Ultrasound in medicine & biology.

Substantia Nigra Hyperechogenicity

D. Berg, T. Toomsoo, P. Taba, 2016, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.